| Quarter | Score |
|---|---|
| 2022-Q1 | 49.4 |
| 2022-Q3 | 40.8 |
| 2022-Q4 | 49.8 |
| 2023-Q2 | 42.0 |
| 2023-Q3 | 48.8 |
| 2023-Q4 | 65.9 |
| 2024-Q1 | 47.1 |
| 2024-Q2 | 45.2 |
| 2024-Q3 | 77.6 |
| 2024-Q4 | 56.3 |
| 2025-Q1 | 59.9 |
| 2025-Q2 | 63.6 |
| 2025-Q3 | 76.8 |
| 2025-Q4 | 75.6 |
| 2026-Q1 | 74.4 |
| 2026-Q2 | 73.4 |
Funds reducing exposure or consensus momentum fading
Within 9.0% of funds' estimated purchase price
2 of 18 tracked funds hold CX. Avg conviction: 0.0%. Net trimming. First tracked at $9.00 (current +9.0% vs tracked).
Oaktree Capital has 0.0% in this stock
Benchmark comparison unavailable
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Oaktree Capital | 0.0% | Reduce |
| Citadel Advisors | 0.0% | Reduce |